Coloplast (CPH: COLO-B) stock: the official figures
Coloplast (COLOPLAST A/S) is listed on Nasdaq Copenhagen under the ticker COLO-B and belongs to the health care sector. In fiscal 2025 it reported revenue of DKK 27,874m and a net profit of DKK 3,636m, according to the annual accounts it filed with the regulator. Its fiscal year ends on 30 September.
Identifiers for Coloplast: ISIN DK0060448595 · LEI 529900NN7SOJ5QG82X67.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | DKK 27,874m | DKK 27,030m | +3.1% |
| Operating profit | DKK 7,201m | DKK 7,320m | −1.6% |
| Net profit | DKK 3,636m | DKK 5,052m | −28.0% |
| Earnings per share | DKK 16.13 | DKK 22.46 | −28.2% |
| Operating margin | 25.8% | 27.1% | −1.2 pts |
| Net margin | 13.0% | 18.7% | −5.6 pts |
| Total assets | DKK 48,367m | DKK 48,073m | +0.6% |
| Equity | DKK 16,122m | DKK 17,942m | −10.1% |
| Cash | DKK 947.0m | DKK 788.0m | +20.2% |
| Operating cash flow | DKK 6,645m | DKK 2,766m | +140.2% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
6 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | DKK 27,874m | DKK 7,201m | DKK 3,636m | DKK 16.13 | Annual report |
| 2024 | DKK 27,030m | DKK 7,320m | DKK 5,052m | DKK 22.46 | Annual report |
| 2023 | DKK 24,500m | DKK 6,771m | DKK 4,783m | DKK 22.21 | Annual report |
| 2022 | DKK 22,579m | DKK 6,439m | DKK 4,706m | DKK 22.14 | Annual report |
| 2021 | DKK 19,426m | DKK 6,155m | DKK 4,825m | DKK 22.67 | Annual report |
| 2020 | DKK 18,544m | DKK 5,854m | DKK 4,197m | DKK 19.74 | — |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Coloplast. Year by year: dividends paid.
Dividends
In fiscal 2025, Coloplast paid DKK 4,958m in dividends, 136.4% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2025 | DKK 4,958m | 136.4% |
| 2024 | DKK 4,720m | 93.4% |
| 2023 | DKK 4,247m | 88.8% |
| 2022 | DKK 4,041m | 85.9% |
| 2021 | DKK 3,830m | 79.4% |
| 2020 | DKK 3,612m | 86.1% |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Frequently asked questions about Coloplast
- How much did Coloplast earn in fiscal 2025?
- Coloplast reported a net profit of DKK 3,636m for fiscal 2025, on revenue of DKK 27,874m. The year before it reported a net profit of DKK 5,052m.
- Does Coloplast pay a dividend?
- In fiscal 2025, Coloplast paid DKK 4,958m in dividends, 136.4% of its net profit, according to its cash flow statement.
- What are the earnings per share of Coloplast?
- They were DKK 16.13 in fiscal 2025, compared with DKK 22.46 the year before.
- Where is Coloplast listed?
- Coloplast is listed on Nasdaq Copenhagen under the ticker COLO-B and belongs to the health care sector.
- What is the ISIN of Coloplast?
- The ISIN of Coloplast is DK0060448595, the international code that identifies its shares. Its LEI, the legal entity identifier, is 529900NN7SOJ5QG82X67.
- Where do the figures for Coloplast come from?
- From the report Coloplast files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the report Coloplast files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.